Results 231 to 240 of about 144,610 (311)
Risk factors for distant recurrence in patients with rectal cancer supporting selection for total neoadjuvant therapy. [PDF]
Slipsager AB +11 more
europepmc +1 more source
ABSTRACT Background and Objectives Colorectal cancer (CRC) has been on the rise in adults younger than 50. Surgical resection is a potentially curative treatment option for patients with colorectal liver metastases (CRLM). The aim of this study was to describe patient and tumor characteristics associated with disease‐specific survival in young patients
Gabrielle Grob +6 more
wiley +1 more source
Correction: Neoadjuvant therapy with cadonilimab in a patient with MSI-H/dMMR colorectal cancer: a case report. [PDF]
Zhou J +6 more
europepmc +1 more source
ABSTRACT Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal tract. We conducted a systematic review and meta‐analysis of studies that developed, validated, or updated clinical prognostic tools to predict survival in adults with primary GIST, identifying 47 eligible studies (38 development and 9 ...
Alice Zhu +7 more
wiley +1 more source
Deep Learning-Based Synthetic Contrast-Enhanced Breast MRI for Monitoring Response to Neoadjuvant Therapy. [PDF]
Sujichantararat S +13 more
europepmc +1 more source
ABSTRACT Background This present systematic review and meta‐analysis aims to compare overall survival (OS), disease‐free survival (DFS), morbidity and mortality outcomes in patients undergoing colorectal first (CRf) versus liver first (Lf) resections with synchronous colorectal liver metastases.
Sofoklis Mavrantonis +3 more
wiley +1 more source
Personalised neoadjuvant therapy, based on tumour characteristics and patient choice, is the best way forward in rectal cancer. [PDF]
Sammour T.
europepmc +1 more source
ABSTRACT Background The role of second surgical opinions (SSOs) in gastrointestinal (GI) cancer care is not well‐defined. While SSOs are common, the impact may depend on whether patients ultimately undergo resection with the same surgeon or with a different surgeon after the SSO.
Areesh Mevawalla +7 more
wiley +1 more source
Dual-target neoadjuvant therapy with denosumab and sunitinib for giant cell tumor of bone: a sarcoma center experience. [PDF]
Mahdal M +7 more
europepmc +1 more source

